Tonmya, a non-opioid sublingual tablet, showed significant pain reduction in 1,000+ patient trials. Targets 10M+ US adults with fibromyalgia. Commercial launch set for Q4 2025.
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
08/15/2025 - 03:44 PM
Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years
Fibro... [22316 chars]